Nexvet Biopharma's P2P Acquisition

Nexvet Biopharma raised a round of funding on July 31, 2017. Investors include Zoetis.

Nexvet develops monoclonal antibody therapies for companion animals (e.g. dogs and cats) using its proprietary PETisation platform technology, which uniquely produces therapies 100% customized to targ…

Articles about Nexvet Biopharma's P2P Acquisition: